Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease
Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease is organized by PVI, PeerView Institute for Medical Education.
Release Date: March 22, 2023
Expiration Date: March 21, 2024
Activity Description:
Preventing and managing graft-versus-host disease (GVHD) remains a significant problem in the post–allogeneic hematopoietic stem cell transplant (HCT) setting. Can a wide range of unique treatment modalities, including costimulatory compounds, targeted agents, and engineered cell therapy, challenge long-standing management protocols in this setting? Find out in this activity, based on a recent live symposium, which features an overview of available and emerging therapeutic options for modern GVHD management as a means to extend the benefits of HCT and provide more effective prophylaxis and treatment.
Educational Objectives:
Upon completion of this activity, participants should be better able to:
• Summarize current safety/efficacy evidence supporting the use of novel therapeutics for prophylaxis or treatment of acute or chronic graft-versus-host-disease (GVHD) in the post-transplant setting
• Develop management plans with novel and emerging therapeutics for the prophylaxis of GVHD in the post-transplant setting, based on current evidence and practice guidelines
• Integrate novel and emerging therapies into safe, personalized treatment plans for the management of acute or chronic GVHD, including novel combinatorial strategies and/or options for second-line management.